VIRX — Viracta Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $0.66m
- -$3.57m
Annual income statement for Viracta Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2.07 | 0.12 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 25.4 | 22.4 | 114 | 50.6 | 50.7 |
| Operating Profit | -23.3 | -22.3 | -114 | -50.6 | -50.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -23.3 | -21.6 | -115 | -49.2 | -51.1 |
| Net Income After Taxes | -23.3 | -21.6 | -115 | -49.2 | -51.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -23.3 | -21.6 | -115 | -49.2 | -51.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -23.3 | -21.6 | -115 | -49.2 | -51.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -9.37 | -5.02 | -0.833 | -1.3 | -1.32 |